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Abstract 
The treatment of lymphomas may result in the development of second malignancies, as 
evident by the numerous reports in the literature. Treatment with cyclophosphamide-based 
chemotherapy regimens may lead to bladder lesions such as haemorrhagic cystitis and also 
to carcinoma of the urinary bladder. Previous pelvic radiotherapy treatment is also 
implicated as a cause for local second cancers. We present the case of a patient treated for 
Hodgkin’s lymphoma, who was diagnosed with transitional cell carcinoma of the bladder 
soon after treatment completion. On completion of 6 cycles of ABVD chemotherapy the 
patient was on follow-up. Two months after treatment completion the patient complained 
of dysuria and was investigated for a suspected urinary tract infection. Urine microscopy did 
not reveal any abnormality. Symptomatic treatment was prescribed and cystoscopy was 
arranged. The cystoscopic findings suggested an irregular growth overlying the trigone and 
the biopsy reported it as transitional cell carcinoma. This case report demonstrates that 
symptoms attributed to common medical causes in patients treated for cancer may be a sign 
of second malignancy. This case report also demonstrates the need for a thorough 
evaluation of patients’ complaints during follow-up, although the likelihood for the 
occurrence of a second malignancy may be low. The assumption that these symptoms were 
due to a commonly occurring urinary tract infection would have had serious implications 
leading to a delay in the treatment of the bladder cancer. 
 
Introduction 
Cyclophosphamide-based chemotherapy is a well-known agent triggering second 
malignancies in many patients. Similarly, radiation-induced cancers, mainly sarcomas 
are commonly seen at sites that have been included in radiation fields.  
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Studies have shown a definite association between treatment for lymphoma and 
development of bladder carcinoma [1]. In some cases this may occur in the backdrop of 
cyclophosphamide-induced cystitis. Uroprotection with Mesna administered during 
chemotherapy has been thought to provide some protection against cystitis in these 
patients. 
Usually, treatment of patients with various alkylating agents induces cancer of many 
different types, which includes that of the kidney and bladder. Statistically, the most 
common secondary malignancies that result from treatment of lymphomas are 
leukemias [2] and many solid tumours, especially cancers of the lung, breast, thyroid, 
bone, soft tissue, stomach, oesophagus, colon and rectum, uterine cervix, head and 
neck, and mesothelioma [3, 4]. These tumours occur primarily after radiation therapy 
or with combined modality treatment, and approximately 75% occur within radiation 
ports. At a 15-year follow-up, the risk of second solid tumours approximates 13% as 
per estimates in the literature [3, 5]. 
Occurrence of bladder cancers has not been commonly documented in patients 
treated with regimens that exclude cyclophosphamide or ifosfamide. Moreover, a 
search of PubMed does not reveal any reports on the incidence of developing bladder 
cancer within a few weeks of completion of chemotherapy in lymphoma patients. 
We present the case of a patient, diagnosed with Hodgkin’s lymphoma, who 
developed bladder carcinoma presenting with features of urinary tract infection within 
8 weeks of completion of chemotherapy. After treatment with transurethral resection 
of the bladder tumour and intravesical immunotherapy, a favourable response to 
treatment was obtained. The patient is presently on follow-up. 
Case Presentation 
Our patient is a 35-year-old man. The patient was in his usual state of health until February 2010 
when he developed multiple swellings on both sides of the neck. Apart from the neck swellings he had 
no other significant complaints, and no loss of weight or fever. Examination revealed multiple firm 
mobile nodes measuring a maximum of 2 cm in diameter involving levels II, III and IV on both sides of 
the neck with no associated tenderness. No other peripheral nodes were palpable. 
The patient underwent a fine needle aspiration of a neck swelling at an outside hospital, which 
revealed features suggestive of a lymphoproliferative disorder. He underwent an excision biopsy of a 
node at our institute. The histology was reported as classical Hodgkin’s lymphoma, mixed cellularity 
type (fig. 1). Systemic workup did not reveal any evidence of disease beyond the neck. He was 
initiated on chemotherapy with ABVD regimen. The response to chemotherapy was favourable and he 
completed 6 cycles of chemotherapy. Post-treatment investigations showed evidence of complete 
response. He was accordingly asked to attend our institute for regular follow-up. During one of his 
follow-up visits on January 5, 2011, he complained of dysuria. Symptomatic medications were 
prescribed and a urine microscopy and Gram stain was requested prior to initiation of antibiotics. The 
patient reported back in a week with no relief of symptoms. No abnormality was found in the 
microscopy and Gram stain report. Cystoscopic evaluation was requested this time. On January 28, 
2011, he underwent cystoscopy. An irregular growth on the bladder mucosa measuring around 1.5 cm 
was noted overlying the trigone and a transurethral resection of the bladder tumour was arranged. 
The entire lesion was resected at its base and fulgurated. No other abnormality was noted on 
inspection of the other areas of bladder mucosa. The histology (fig. 2) revealed transitional cell 
carcinoma that had invaded the lamina propria. Muscle invasion was not reported. 
Treatment options for further management of his bladder tumour were discussed. It was agreed 
that he would receive intravesical BCG. He started his first dose of intravesical treatment (120 mg) on  
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February 10, 2011. He tolerated the 6 doses of weekly intravesical BCG well, with occurrence of mild 
cystitis at week 5, which did not require treatment interruption. A cystoscopy done on completion of 
the 6 doses on March 30, 2011 showed no recurrence or any new lesion elsewhere on the mucosa. It 
was agreed with the patient that he would proceed with maintenance therapy at three-monthly 
intervals for 1 year. Check cystoscopies at three-monthly intervals were performed. His cystoscopy 
done on January 24, 2012 did not show any evidence of disease. He is now on follow-up.  
Discussion 
Second malignancies represent an important iatrogenic complication of the 
treatment of neoplasms. Hodgkin’s disease has been treated mainly with two 
chemotherapy schedules, MOPP (nitrogen mustard, Oncovin, procarbazine and 
prednisone), which includes alkylating agents, and ABVD (Adriamycin, bleomycin, 
vinblastine and dacarbazine), which includes topoisomerase II inhibitors. Due to the 
types of agents used, patients with Hodgkin’s disease often develop secondary 
leukemias. As noted by Salas et al. [6], specific cytogenetic changes are associated with 
the therapy-related myelodysplastic syndrome or therapy-related acute myeloid 
leukemia that occurs as a sequela of their chemotherapy. Interestingly, they noted that 
at the cytogenetic level, patients treated with alkylating agents and with topoisomerase 
II inhibitors show distinct genetic alterations. These findings potentially have a bearing 
on the prognostication and treatment of these haematological malignancies. 
Among patients of Hodgkin’s lymphoma, follow-up data in long-term survivors 
suggest a significant risk of second solid tumours as well, with the risk of certain 
cancers remaining significantly high in these patients. Data analysed by Dores et al. [4] 
from population-based cancer registries across North America and Europe revealed 
significantly elevated risks of stomach, female breast, and uterine cervix cancers up to 
25 years after treatment completion in Hodgkin’s disease survivors. 
Várady et al. [7] reported that fewer than 5% of 665 patients treated for Hodgkin’s 
lymphoma at their institute from 1978 to 1996 developed second malignancies. These 
patients had received either chemotherapy alone or both chemotherapy and 
radiotherapy. Haematological malignancy occurred after a mean interval of 6.1 years 
from treatment completion. This was attributed to the alkylating agents they had 
received for treatment of Hodgkin’s lymphoma. 
Solid tumours that occurred included mostly carcinomas, but also sarcomas and 
melanoma. Quite a few of these were found in previously irradiated regions. The mean 
latency period to developing the second cancer in patients developing solid tumours 
was 8.3 years. 
Maurizi et al. [8] attempted to examine the occurrence of solid tumours in relation to 
the different types of therapy (radiotherapy, chemotherapy and radiochemotherapy; 
splenectomy or splenic irradiation versus no splenectomy-no splenic irradiation) 
received by patients treated for Hodgkin’s disease. The average follow-up period was 
72 months. Their patients had received ABVD or MOPP/ABVD hybrid chemotherapy 
regimens as sole or part of their treatment. According to multivariate analysis, their 
findings supported that increasing age, specifically >40 years, at the time of diagnosis of 
Hodgkin’s lymphoma is the most important factor in the risk of developing solid  
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tumours. They also noted that treatment of Hodgkin’s lymphoma with chemotherapy 
alone increases the risk of second solid tumours. 
Bonadonna et al. [9] reported their experience regarding survival in 811 patients 
with intermediate and advanced Hodgkin’s lymphoma treated at the Milan Cancer 
Institute. They noted that ABVD chemotherapy was more efficacious than the MOPP 
regimen in significantly reducing the risk of lymphoma progression and death. 
However, they noted that a significant risk of developing second cancers also remained, 
especially in those receiving extensive irradiation. In their group the total risk of 
developing a second malignancy was 22.2%. 
The analysis by Valagussa et al. [10], with a median 43 months of follow-up revealed 
that solid tumours occurred only in patients given radiotherapy with or without 
adjuvant chemotherapy, and acute non-lymphoblastic leukemia occurred only after 
treatment with MOPP or modified MOPP regimens. Neither solid tumours nor acute 
non-lymphoblastic leukemia occurred in patients given ABVD. 
Valagussa et al. [11] reported on a retrospective analysis of 1,032 patients with 
Hodgkin’s disease admitted to their Institute between 1965 and 1978 and treated with 
radiotherapy or chemotherapy or both modalities. The analysis revealed that within 10 
years from initial therapy, no patient receiving ABVD developed second cancers, 
whether they received radiotherapy or not. This prompted them to report that there 
was an absence of treatment-induced second neoplasms after ABVD chemotherapy in 
Hodgkin’s disease. 
As survival rates in Hodgkin’s lymphoma have improved over the years the side 
effects related to treatment are a matter of concern in these patients, especially the 
occurrence of second cancers. With advances in treatment, there has been significant 
modification of chemotherapy agents, shifting to safer drugs that reduce not only the 
chance of second malignancies but also other side effects including fertility issues. As 
noted in the literature, the ABVD chemotherapy widely in use is safer and has done 
away with some of the issues associated with MOPP or MOPP hybrid chemotherapy. 
More efficient chemotherapy has made magna field irradiation a thing of the past in 
Hodgkin’s lymphoma treatment. There has also been a paradigm shift in radiotherapy 
delivery techniques, which have greatly reduced volumes of tissue receiving the 
prescription dose. Safer treatment has transformed survival and side effects in these 
patients. Consequently, surveillance for second cancers is of great importance in this 
group. 
Numerous reports in the literature suggest that cyclophosphamide-treated patients 
are at a greater risk of developing bladder carcinoma, and the risk may be 4- to 10-fold 
higher than in the general population [12, 13]. The use of cisplatin and delivery of 
radiotherapy to the pelvis have also been implicated as risk factors for future 
development of bladder carcinoma [14]. Despite the extensive number of reports on 
the occurrence of bladder carcinoma due to different chemotherapy regimens with or 
without radiation therapy, no reports linking bladder cancers to ABVD chemotherapy 
have been noted on a comprehensive search of the literature. 
The occurrence of bladder carcinoma after ABVD chemotherapy and that too within 
a short period of treatment completion is very rare. Our experience emphasizes the 
need for a higher degree of suspicion regarding the development of second cancers  
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during follow-up of patients treated for lymphoma. With improved survival, early 
detection and treatment of solid tumours that may arise as a consequence of treatment 
of Hodgkin’s lymphoma is of immense importance. It is essential that at each follow-up 
visit any new symptoms are carefully followed up and investigated in these patients. 
Not all patients presenting with second cancers will have received the chemotherapy 
agents reportedly linked to that particular tumour type. 
 
 
 
 
 
 
Fig. 1. Histology of excised node showing mixed cellularity Hodgkin’s lymphoma. 
 
 
 
Fig. 2. Histology of bladder growth removed by transurethral resection. 
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